Scalper1 News
Specialty drugmaker Depomed (DEPO) popped nearly 10% to a new high and got an upgrade from Roth Friday after it inked a deal to acquire a new pain drug for $1.05 billion. Late Thursday, Depomed agreed to buy the Nucynta franchise from the Johnson & Johnson (JNJ) Janssen Pharmaceuticals division. The franchise includes a tablet, an extended-release tablet and an oral solution that has yet to be launched. Nucynta had been drawing $166 million a year Scalper1 News
Scalper1 News